Evidence map›Paper›PMID 28974828›Full record

Observational studyMedical archives (Sarajevo, Bosnia and Herzegovina)2017

Does Dexamethasone Helps in Meningococcal Sepsis?

Ilir Tolaj, Hamdi Ramadani, Murat Mehmeti, Hatixhe Gashi, Arbana Kasumi, Visar Gashi, Haki Jashari

Abstract readObservational Study
In one paragraph

Observational study in Medical archives (Sarajevo, Bosnia and Herzegovina), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ilir TolajDepartment of Infectious Diseases, University Clinical Centre in Pristina, Kosovo.
Hamdi RamadaniDepartment of Infectious Diseases, University Clinical Centre in Pristina, Kosovo.
Murat MehmetiDepartment of Infectious Diseases, University Clinical Centre in Pristina, Kosovo.
Hatixhe GashiDepartment of Infectious Diseases, University Clinical Centre in Pristina, Kosovo.
Arbana KasumiDepartment of Infectious Diseases, University Clinical Centre in Pristina, Kosovo.
Visar GashiDepartment of Infectious Diseases, University Clinical Centre in Pristina, Kosovo.
Haki JashariDepartment of Infectious Diseases, University Clinical Centre in Pristina, Kosovo.
University Clinical Center of Kosovo · XK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePrompt recognition and aggressive early treatment are the only effective measures against invasive meningococcal disease (IMD). Anti-inflammatory adjunctive treatment remains controversial and difficult to assess in patients with IMD. The purpose of this study was to evaluate the effect of dexamethasone (DXM) as adjunctive treatment in different clinical forms of IMD, and attempt to answer if DXM should be routinely used in the treatment of IMD.

methodsIn this non-interventional clinical study (NIS), 39 patients with meningococcal septicaemia with or without of meningitis were included, and compared regarding the impact of dexamethasone (DXM), as an adjunctive treatment, on the outcome of IMD. SPSS statistics is used for statistical processing of data.

resultsThirty (76.9%) patients with IMD had sepsis and meningitis, and 9 (23.1%) of them had sepsis alone. Dexamethasone was used in 24 (61.5%) cases, in both clinical groups. The overall mortality rate was 10.3%. Pneumonia was diagnosed in 6 patients (15.4%), arthritis in 3 of them (7.7%), and subdural effusion in one patient (2.6%). The data showed a significant statistical difference on the length of hospitalization, and WBC normalization in groups of patients treated with DXM.

conclusionThe use of DXM as adjunctive therapy in invasive meningococcal disease has a degree of proven benefits and no harmful effects. In fighting this very dangerous and complex infection, even a limited benefit is sufficient to recommend the use of DXM as adjunctive treatment in invasive meningococcal disease.

Indexed as

AdolescentAdultAnti-Inflammatory AgentsArthritis, InfectiousChemotherapy, AdjuvantChildChild, PreschoolDexamethasoneFemaleHospitalizationHumansInfantInfant, NewbornMaleMeningitis, MeningococcalPneumonia, BacterialAnti-Inflammatory AgentsDexamethasonedexamethasone (DXM)meningitisN. meningitidissepsis

Identifiers

PMID28974828
PMCPMC5585801
OpenAlexW2729238059

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.